Company Research Report: Carenostics
Company Overview
- Name: Carenostics
- Mission: To tackle the underdiagnosis, undertreatment, and health inequities of chronic disease by empowering clinicians with AI.
- Founded By: Bharat Rao and Kanishka Rao
- Key People:
- Bharat Rao: Co-Founder and CEO
- Kanishka Rao: Co-Founder and COO
- Headquarters: No information is available
- Number of Employees: No information is available
- Revenue: No information is available
- Known For: Carenostics is renowned for integrating AI and machine learning technologies with provider Electronic Health Records (EHR) data to identify high-risk, undiagnosed chronic disease patients to help clinicians intervene earlier.
Products
1. AI-Driven Clinical Decision Support
- Description: A platform utilizing machine learning on patients' EHR data to enable early intervention for chronic diseases.
- Key Features:
- Identification of high-risk patients
- Earlier clinical intervention
- Tackling health inequities
2. CKDx: Identifying and Intervening on Stage 3+ CKD
- Description: Specialized in identifying undiagnosed Stage 3+ Chronic Kidney Disease (CKD) patients.
- Key Features:
- Prediction of disease progression to ESRD
- Recommendations for guideline-based therapies
- Predictions for potential hospitalizations and complications
3. ADx: Finding and treating patients with uncontrolled asthma
- Description: AI solution to improve asthma treatment success rates by identifying and treating patients with poor symptom control.
- Key Features:
- Promotes proper diagnosis
- Highlights guideline-supported treatments
4. Precision Medicine for Opioid Use Disorder
- Description: An AI solution to provide precision medicine for treating opioid addiction.
- Key Features:
- Identifies key factors promoting treatment success
- Offers personalized treatment recommendations
Recent Developments
- Partnerships & Recognitions:
- Bayer G4A Investment (2022): Selected as the only investment for Bayer's G4A growth track for addressing healthcare inequities in chronic disease management.
- Partnership with Hackensack Meridian Health (HMH): Deployment of AI solutions at HMH for Stage 3 chronic kidney disease since 2022.
- Awards and Nominations:
- 2023 Bio-IT World Innovative Practices Award: Recognized alongside prominent companies for AI-driven tool used to diagnose CKD.
- Rising Star at 5th Annual Digital Health Hub Foundation Awards (2023).
- Funding:
- Raised $5 million in Seed funding led by M13 in September 2023.
- Recent News:
- Finalist for Technology Startup of the Year at the 2024 Enterprise Awards.
- Co-Founder & COO, Kanishka Rao's presentation on AI's role in addressing chronic disease at the GenAI Salon in April 2024.
Conclusion
Carenostics positions itself as a leading healthcare AI innovator, focusing on early detection and treatment intervention to address chronic disease underdiagnosis and health inequities. Through strategic partnerships, such as with Bayer G4A and HMH, and recognition from prestigious awards, Carenostics continues to expand its impact in the healthcare sector.
